a5496i
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of April 2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca divestment of Movantik to RedHill Biopharma
completed
2 April 2020 07:00 BST
AstraZeneca divestment
of Movantik to RedHill Biopharma
completed
AstraZeneca has completed the previously
communicated agreement to
sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and
Israel, to RedHill Biopharma (RedHill).
AstraZeneca will continue to manufacture and
supply Movantik to RedHill during a transition period. In
2015, AstraZeneca entered into a co-commercialisation agreement
with Daiichi Sankyo, Inc. for Movantik in the US, which has now been transferred to
RedHill.
Financial considerations
Under the terms of the agreement, AstraZeneca has received a
payment of $52.5m from RedHill. The Company will also receive a
further non-contingent payment of $15m in 2021. Income arising from
the upfront payment, offset by a charge
for derecognition of the associated intangible
asset, and the future payment will be reported in
AstraZeneca's financial statements within Other Operating Income
& Expense. In 2019, Movantik generated sales of $96m in the US. The
agreement will not impact the Company's financial guidance for
2020.
Movantik
Movantik (naloxegol) is a
once-daily oral peripherally
acting mu-opioid receptor antagonist approved by the US Food and Drug
Administration for the treatment of OIC in adult patients with
chronic non-cancer pain. Movantik was licensed from Nektar Therapeutics in
2009. It was developed using Nektar's oral small-molecule polymer
conjugate technology. In 2016, AstraZeneca divested the rights
in Europe to ProStrakan Group (now KKI) and the rights in
Canada and Israel to Knight Therapeutics.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal and Metabolism, and Respiratory.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients
worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
02 April
2020
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|